Zinc Sulfate for Human Papillomavirus (HPV)

Status Terminated

Clinical Trial Summary

The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high risk HPV versus placebo.

Clinical Trial Description

Upon enrollment eligible participants will be randomized and given a three-month supply of zinc sulfate or placebo to be taken as directed. They will have zinc serum lab testing at enrollment and upon study completion. Patients will also be asked to complete short questionnaires and to make study staff aware of any side effects they should experience. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03404310
Study type	Interventional
Source	Spectrum Health Hospitals
Contact
Status	Terminated
Phase	N/A
Start date	October 24, 2017
Completion date	June 28, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05329961` - Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study	Early Phase 1
Completed	`NCT05862844` - Promise Women Project	N/A
Active, not recruiting	`NCT04199078` - Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.	N/A
Recruiting	`NCT05566106` - Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
Not yet recruiting	`NCT06436274` - Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.	Phase 4
Not yet recruiting	`NCT06229353` - Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
Completed	`NCT01757392` - Candin Safety & Efficacy Study for the Treatment of Warts	Phase 2
Active, not recruiting	`NCT04716127` - A Proximity-incentive Strategy for Cervical Cancer Screening	N/A
Recruiting	`NCT05210348` - Clinical Evaluation of Detection of High Risk HPV in Urine
Recruiting	`NCT05835947` - Anal Cancer Risk In Women
Not yet recruiting	`NCT03947775` - HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL	Phase 2
Recruiting	`NCT03302858` - A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand	Phase 2
Completed	`NCT03082950` - HPV Infections, Cancer of the Vulva and Therapeutical Success
Active, not recruiting	`NCT04950101` - Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis	N/A
Recruiting	`NCT05146895` - A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts	N/A
Completed	`NCT04002154` - Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV	N/A
Recruiting	`NCT04232917` - Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.	Phase 4
Active, not recruiting	`NCT03729518` - TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck	N/A
Recruiting	`NCT05640700` - Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
Recruiting	`NCT05362669` - SMS Messaging for Invitation in the Cervical Cancer Screening Programme	N/A